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2 
Abstract 
 
Background 
For CAM to feature prominently in health care decision-making there is a need to expand 
the evidence-base and to further incorporate economic evaluation into research priorities.   
In a world of scarce health care resources and an emphasis on efficiency and clinical 
efficacy, CAM, as indeed do all other treatments, requires rigorous evaluation to be 
considered in budget decision-making.   
Methods 
Economic evaluation provides the tools to measure the costs and health consequences of 
CAM interventions and thereby inform decision making.  This article offers CAM 
researchers an introductory framework for understanding, undertaking and disseminating 
economic evaluation.  The types of economic evaluation available for the study of CAM 
are discussed, and decision modelling is introduced as a method for economic evaluation 
with much potential for use in CAM.  Two types of decision models are introduced, 
decision trees and Markov models, along with a worked example of how each method is 
used to examine costs and health consequences.  This is followed by a discussion of how 
this information is used by decision makers. 
Conclusions 
Undoubtedly, economic evaluation methods form an important part of health care 
decision making.  Without formal training it can seem a daunting task to consider 
economic evaluation, however, multidisciplinary teams provide an opportunity for health 
economists, CAM practitioners and other interested researchers, to work together to 
further develop the economic evaluation of CAM. 
 
 
Background 
Economic evaluation is discussed often in the conventional health care literature and it   
is well established that clinical efficacy and cost-effectiveness evidence are necessary to 
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assist health care decision-making within the confines of finite health budgets.  Research 
examining the safety and efficacy of Complementary and Alternative Medicine (CAM) is 
rapidly growing [1], and there appears to be a potential role for CAM in a number of 
treatment areas [2].  In order for CAM to be extensively considered in health care 
decision-making there is a need to expand the evidence-base for these medicines and 
therapies and for the CAM research community to further incorporate economic 
evaluation into research priorities (alongside developing a broader health services 
research agenda) [3].  The aims of this article are to discuss the need for economic 
evaluation, outline the types of economic evaluation available for the study of CAM, and 
introduce decision modelling as one flexible method for economic evaluation with much 
potential for use in examining and assessing CAM. Our discussion offers CAM 
researchers an introductory framework for understanding, undertaking and disseminating 
economic evaluation.  It is hoped that this paper will help fuel enthusiasm and develop 
early capacity towards producing much needed rigorous economic evaluation of CAM. 
. 
A Growing Need for Economic Evaluation in CAM. 
In a world of scarce health care resources and an emphasis on efficiency and clinical 
efficacy, CAM (like all treatments) requires rigorous evaluation if it is to be fully 
considered in budget decision-making [4].  While the research base for CAM is small 
relative to that for conventional medicine,  it is growing [1] and evidence shows some 
CAM therapies are safe and effective [2].  A logical next step is to examine the ‘real 
world’ impact of CAM; whether it offers value for money in comparison to, or in 
addition to, conventional treatments.  Any informed attempt to consider CAM provision 
as a core component of a comprehensive and integrated health care system requires a 
focus upon associated change to costs and health benefits [5, 6]. Economic evaluation 
methods provide the tools to measure the costs and health consequences of CAM 
interventions and thereby inform decision making.   
 
The number of published health economic evaluations in Australia and around the world 
is rapidly increasing.  Some researchers have identified economic evaluation and its 
importance in relation to CAM [7, 8] and there are several systematic reviews which have 
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examined the number and quality of economic evaluations which currently exist in the 
CAM literature [9, 10].  One recent systematic review concluded there was a limited 
number of evaluations of sufficient quality to draw general conclusions.  Nevertheless, 
this review did consider a small number of treatment areas as cost-effective compared 
with conventional care, including the use of acupuncture for migraines, manual therapy 
for neck pain, and spa therapy for Parkinson’s disease.  There was also evidence to 
suggest CAM can be considered cost effective in a complementary role in the treatment 
of some conditions, for example complementary guided imagery for cardiac surgery 
patients and complementary relaxation therapy for patients with a previous myocardial 
infarction.  It is perhaps easier to consider that CAM approaches which are substitutes for 
conventional care are more likely to be cost-effective, however, there is also evidence for 
CAM in a complementary role, despite the addition of another treatment [6].   
 
CAM evaluation does face potential challenges given CAM’s different philosophical 
tenets when compared to conventional medicine [11].  Treatment is often a complex 
combination of several therapies tailored to the individual [1], and the therapeutic effects 
of CAM are often small, difficult to quantify and can occur over a long period, whether 
administered as a stand alone treatment or provided in addition to conventional medicine.  
It is important to use the evaluation framework whilst incorporating CAM-sensitive 
outcome measures and to focus on the development of outcome measures which capture 
the effects of CAM and study designs which allow these outcomes to be examined.  As 
such, it is essential that this area be developed through collaboration between CAM 
practitioners and health services researchers, to ensure economic evaluation research is 
conducted in a manner which captures the broad benefits of CAM.   
 
In order to address the gap in research and help others develop capacity in this significant 
area of CAM-related inquiry, this paper provides an overview of economic evaluation, 
and introduces the concept of decision modelling as a method for economic evaluation 
ideal for CAM.   
 
5 
Methods 
 
Economic Evaluation for CAM 
Different schools of thought in economic evaluation 
There are two schools of thought in economic evaluation, described in brief here due to 
extensive description elsewhere in the CAM literature [1, 6, 8].  Costs are consistently 
measured in monetary units, benefits are measured in different ways.  Cost-benefit 
analysis (CBA) summarises benefits in monetary values, enabling a direct comparison 
between costs and outcomes.  Using CBA anything can be compared and health goals can 
be compared with non-health goals.  Individual preferences are valued, often using the 
concept of willingness to pay (WTP).  CBA can be difficult to apply as giving health 
outcomes monetary value can be problematic [12].  In contrast, cost effectiveness 
analysis (CEA) and cost-utility analysis (CUA) are useful for allocating a fixed health 
budget between competing treatments to maximise health improvements.  CEA is used 
when programs or treatments have a common outcome of interest to compare.  CUA is 
similar, except for a focus on the quality of the outcome, incorporating a sense of value or 
preference as captured by the use of quality adjusted life years (QALYs) [13, 14].  The 
concept of the QALY was designed to capture changes to both quantity and quality of life 
from a treatment or intervention [15].  QALYs are calculated by weighting the extra time 
spent alive because of an intervention with a utility value, known as the QALY weight. It 
represents a preference based valuation of a  particular health state and allows both 
quantity and quality to be summarised in a single measure [15, 16].  The scale of QALY 
weights is for death to equal 0 and perfect health to equal 1. Two extra years of life in a 
state value at 0.7 is equal to 1.4 QALYs. 
As an example of utility weights, a recently published study derived estimates for the 
stages of chronic heart failure, New York Heart Association (NYHA) class I, II, III, and 
IV had weights of 0.90, 0.83, 0.74, and 0.60 respectively.  NYHA class I is an 
asymptomatic stage of heart failure, and so the value of that particular state is close to 
perfect health.  On the other hand NYHA class IV is associated with persistent symptoms 
despite optimal medical treatment, and therefore the value of that state is further from 
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perfect health [17].  The suitability of QALYs as a measure of outcome is a complex 
issue which has been discussed in both conventional and CAM literature [1, 4, 14, 18-
20].  Currently available full economic evaluations for CAM have all utilised CEA or 
CUA, perhaps because they are more easily applied than CBA requiring the valuation of 
health in monetary terms.  For a comprehensive discussion of CBA versus CEA please 
refer to a Resources for the Future (RFF) report written by Alan Krupnick [21].  
 
Decision analytic modelling has become increasingly popular as a method for the 
economic evaluation of health care.  It is a flexible method which has not been previously 
discussed in reference to CAM.  A full critique of this approach is beyond the scope of 
this paper, but can be found in the literature [22].  Randomised clinical trials (RCTs) can 
provide valuable information about treatment effectiveness and have often been used as 
the single source of data for economic decision making [23].  There are limitations to 
using only RCT data for economic evaluation.  Decisions are often made between 
multiple competing options, which are unlikely to have been compared in a single trial.  
RCTs are often based on very strict criteria that reduces the ability to generalise the 
results.  Often not all of the factors of interest are measured, intermediate measures are 
often used instead of final endpoints; and the timeframe for RCTs is often short, whereas 
lifetime costs are important when compiling economic evidence [24].   
 
Decision analytic modelling provides an opportunity to use multiple data sources and 
extrapolate beyond the limits of current clinical evidence in order to include alternative 
interventions [25].  Other benefits include the provision of a natural structure which 
identifies the possible states that patients may be in and the effect of the interventions on 
these states; a method of transforming the evidence into estimates of costs and benefits 
for comparison; an assessment of the uncertainty present in the comparison of 
interventions; and identification of the value of future research to further inform decisions 
[14]. 
 
Decision analytic models 
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Development of model structure is a crucial part of the research process, the aim is to 
develop a model which is no more complex than it needs to be to answer the questions 
posed. They should be designed to represent important outcomes and estimate the 
relevant costs and health benefits, for each choice under consideration. Decision trees and 
Markov models are two common choices of models.  
 
A simple decision tree is drawn in Figure 1.  This represents a hypothetical case of 
chronic heart failure and treatment with current therapy and a new therapy comprised of 
the current treatment, with CAM introduced as a complement.  It shows: a decision at the 
square ‘decision node’, and this is where a decision to adopt one therapy over the other is 
summarised ;  the alternate events that  might occur at the circular ‘chance nodes’, which 
in this example are improvement or deterioration;  and the final cost and health benefits 
of every possible pathway at the triangular ‘terminal nodes’.  The expected economic 
values arising from each decision are the product of the final costs and health benefits 
and the likelihood of the alternate events, known as probabilities.  The tree is rolled back 
from right to left. 
 
Probabilities for a given treatment must sum to 1, in this example for current therapy, the 
probability of improvement is 0.6 and the probability of deterioration is 0.4, summed 
together they equal 1.  Probabilities are based on available information which may come 
from a variety of sources, including clinical trials, observational studies, case series, 
expert opinion, or a secondary analysis of any of the above sources [26].  The 
probabilities used and the quality of the data source will impact on the analysis, 
sensitivity analysis is performed to assess this impact [14].   
 
There are a range of costs to consider.  These include health system costs, such as drugs, 
hospitalisation, equipment, medical staff; costs to other sectors; patient/family costs, such 
as travel costs and time; and productivity costs, the effect of work time.  The range of 
costs included in the evaluation will depend upon the viewpoint taken in the analysis.  
For example, travel costs incurred by the patient and patient’s family members and the 
cost of time away from work are likely to be important from the point of view of the 
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patient and society, however, it is may not be as important to the government [14].  There 
are two components of determining costs, the quantity of resources used and the market 
price of the resources.  For example, if we consider the price of medication, conventional 
and CAM approaches, for heart failure and the cost of an outpatient visit to a medical 
practitioner, we must first establish what medications are taken, in what amounts and 
their price, and then how many outpatient visits a person with heart failure would have in 
addition to the price of the visit, or some approximation of the price.  The information for 
this comes from a variety of sources, including published cost data, administrative 
databases, such as those held by the Australian Institute of Health and Welfare (AIHW), 
previous economic evaluations and expert opinion [26].   
 
Calculations of expected costs and outcomes from the data drawn in Figure 1 are shown 
here: 
 
Expected cost of current treatment =   (0.6 x $500) + (0.4 x $600) = $540 
Expected cost of new treatment = (0.7 x $520) + (0.3 x $620) = $550 
Expected QALYs of current treatment = (0.6 x 10) + (0.4 x 5) = 8 
Expected QALYs of new treatment = (0.7 x 10) + (0.3 x 5) = 8.5 
 
 
Using the expected costs and benefits calculated, an Incremental Cost Effectiveness Ratio 
(ICER) can be calculated, which tells us the incremental cost per additional QALY 
generated by the new treatment.  Information like this can be used to compare competing 
treatments and provide information about their value for money. 
 
Calculation of the ICER = ($550-$540)/ (8.5-8) = $20 per QALY. 
 
Decision trees have limitations: time is not made explicit, and they quickly become large 
and unwieldy when dealing with long timeframes and multiple events, becoming visually 
and computationally complex. 
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Markov models are an alternate approach to decision analytic modelling and have added 
flexibility and are suitable for more complex situations.  There are a series of mutually 
exclusive ‘states’ drawn in Figure 2 which a patient can occupy at a given point in time 
instead of branches in a decision tree.  Time is represented explicitly, the probability of a 
patient being in a particular state at a particular point in time is examined over a series of 
cycles.  Movement between the states is determined by the calculation of transition 
probabilities which reflect ‘real life’ disease progression.  Transition probabilities capture 
the chance of maintaining the same level of health, improvement, deterioration or death.   
 
CAM is often complex as well as often used by those with chronic disease and those 
seeking long-term prevention.  Markov models are ideally suited to complex chronic 
disease and may be ideal for the economic evaluation of CAM due to the added 
flexibility and ability to represent complex situations. 
 
In Figure 2 we show the probability of a patient moving between states and remaining in 
states for each cycle of the model for a ‘current treatment’ alternative. This information is 
also shown as a transition matrix in table 2. Note that the sum of each row must add up to 
1, and this ensures that no patient can leave the model. 
 
Different values for the transition probabilities will be used for alternate treatments that 
compete with the current treatment. A new more effective treatment might for example 
take a lower value for the probability of moving from ‘Improvement to ‘Deterioration’ 
and from ‘Improvement’ to ‘Death’. This is shown in Table 3.  
 
Under any competing treatment alternative the movements of say 1,000 patients between 
health states over time (cycles) can be summarised, in this case one cycle lasts one year. 
Patient movements through the Markov model are shown in Table 4 for the current 
treatment probabilities, for the first three cycles. One thousand patients are always 
retained in the model. 
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Each row of the table represents a cycle during which time patients incur costs from 
treatment and accrue health outcomes shown by the utility score. Once the number of 
patients in each state for each cycle has been calculated, we can calculate the total costs 
and benefits for a treatment option. We need to know the cost and benefit associated with 
being in each state, which are shown in Figure 2. To calculate costs for each cycle, the 
number of patients in each state is multiplied by the cost of that state and then summed 
for all the states for that cycle.  To calculate benefits for each cycle, the proportion of 
patients in each state is multiplied by the utility value of each state and then summed for 
all the states for that cycle. 
 
The costs for current treatments in cycle 1 are (700* $200) + (200*$250) + (100*$0) = 
$190,000. The health benefits for cycle 1 are (700*0.8) + (200*0.5) + (100*0) = 660 
QALYs. The total cost of three cycles (three years) for the current treatment is $496,300 
and total QALYs is 1,652.2. When the new treatment probabilities are used in the model 
the costs change to $513,550 and total QALYs is 1782.7. As with the decision tree, an 
ICER is then calculated. 
 
Calculation of the ICER=($513,550-496,300)/(1782.7-1652.2) = $132.18 per QALY. 
 
For both modelling approaches data are required to inform probabilities of events under 
competing treatment options and the costs and health outcomes that arise. To identify the 
data that can be used to describe the models parameters a process of evidence synthesis is 
required. 
 
 
evidence synthesis 
 
Appropriate evidence for all parameters of the model needs to be identified to ensure the 
reliability of the model.  The evidence base will consist of studies from diverse sources 
and the quality of evidence differs between studies.  This is of particular relevance for 
CAM, as there are often quality issues due to difficulties with study design and the use of 
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small samples.  Evidence needs to be systematically searched and identified, and there 
are many documented methods for this [27].  The multiple sources of evidence include 
randomised controlled trials (RCTs), observational studies, cohort studies, administrative 
databases, expert opinion, clinical outcome registers, cost information, and routine 
statistics. 
 
Evidence synthesis, the process of bringing all the information together, is a crucial step 
in the process of economic evaluation and decision analytic modelling.  Meta-analysis is 
a common method for the synthesis of quantitative data, providing a numerical summary 
of the overall effectiveness of an intervention [28].  The quality of data included in the 
model will determine the model validity, especially when this data is used for parameters 
which have a large influence on the model results.  Therefore transparency is vital when 
presenting the methods of economic evaluation.  The reader needs to be able to see the 
data, the methods used for analysis and the assumptions made, in order to make an 
informed decision about model validity. 
 
It is often argued that CAM is under-researched, and when evidence exists it is often of 
poor quality.  Whilst the process of evidence synthesis and the ability to incorporate 
multiple data sources of varying quality do not replace rigorous research or negate the 
need to expand the evidence base, they do provide an opportunity to examine the current 
evidence base and use the data available to make a decision.  The adept modeller will 
characterise the role of uncertainty in the decision they are informing. Methods exist, that 
are beyond the scope of this article, for describing uncertainty, and should be used for 
any applied modelling study. 
 
 
How information from models should be used by decision makers 
 
The results of cost-effectiveness data we found from the Markov model analysis can be 
shown graphically using the cost-effectiveness plane (see Figure 3).  In this diagram, the 
horizontal axis represents the difference in effect between the intervention of interest and 
the alternative.  The vertical axis represents the difference in cost between the two 
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interventions.  The slope of the line represents the ICER (refer to Table 5).  In this case 
the new treatment lands on a point in quadrant I (i.e., ‘A’)  the intervention is more costly 
and more effective, if it lands on a point in quadrant II (ie., ‘B’) the intervention is less 
costly and more effective (it dominates the alternative), if it lands on a point in quadrant 
III (ie., ‘C’) the intervention is less costly and less effective, and if it lands on a point in 
quadrant IV (ie., ‘D’) it is more costly and less effective (it is dominated by the 
alternative intervention).  If the intervention is located on a point in quadrant I or 
quadrant III a decision must be made as to whether the benefits of the more effective 
intervention are worth the extra costs involved. 
 
The situation where one intervention is more effective and more costly than another 
occurs relatively often (ie., ‘A’).  If this occurs, the decision regarding whether the 
benefits of the more costly intervention are worth the extra costs will depend upon the 
threshold for the decision maker or the willingness-to-pay per unit of health gain (such as 
per QALY or per life year).  There are many suggestions in the literature as to what 
constitutes an appropriate threshold value, but in reality this is an arbitrary figure and 
decision makers do not use such an absolute threshold [29, 30].  It is necessary to have 
some threshold guidance for health care decisions, as the supply of new and effective 
technologies increases and the access to health care improves, there will be increased 
pressure on the health care budget which requires a consistent method for determining 
which interventions or therapies are worth funding [31].  The National Institute for 
Clinical Excellence (NICE) takes the view that at £5000-£15 000/QALY interventions 
are likely to be acceptable, at £25 000-£35 000/QALY special reasons would be needed 
to accept the intervention.  Decisions are made on a case-by-case basis, and as the ICER 
increases the likelihood of rejection also increases [32].     
 
Along with production efficiency, decision makers must consider affordability.  A focus 
only on a threshold would lead to an infinite increase in costs.  This is because many 
programmes, more than can be afforded, may fall below a threshold. The economic 
reality is that health resources are scarce and it may not be possible to increase the health 
care budget, if we recommend an option which increases costs, additional funds will have 
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to be taken from elsewhere and redirected toward the new intervention.  The cost of 
losing currently funded programs must be known before any final decision is made [33]. 
 
The results of economic evaluation are often not incorporated into decision making.  
Reasons for this include limited dissemination of the results, a lack of recognition of the 
implications of the results, poor understanding of the process of economic evaluation, a  
lack of belief in the results, and a lack of political power to enact change based on the 
results [14].  Where decisions have been made based on the results of economic 
evaluation, there are several factors taken into consideration.  A cost-effectiveness 
threshold is applied, above which decisions are increasingly unlikely to be in favour of 
adopting the intervention and below which the intervention is usually adopted.  Cost-
effectiveness is considered in conjunction with the level of uncertainty surrounding the 
results and the burden of the disease under consideration.  Social value judgements 
concerning equity, fairness, and what is considered to be good for society may also 
influence the decision [32].   
 
It is clear that decisions in health care will always be made in the midst of a complex 
interplay of political, social and economic factors.  However, economic evaluation is 
used to inform decisions, for example, the Australian breast and cervical screening 
programs were developed in conjunction with economic evaluation [34].  Whilst 
currently mostly restricted to pharmaceuticals, many jurisdictions now require economic 
evidence to accompany funding requests.  With requirements for this evidence growing 
amidst scarce resources and fixed health budgets, it is reasonable to assume that such 
evidence will become an essential requirement for all interventions and therapies under 
consideration [35].   
 
NICE in the United Kingdom is an organisation which uses economic evaluation and 
cost-effectiveness as the basis for decisions.  The role of NICE is to provide 
recommendations concerning which new and existing technology should be funded by 
the National Health Service (NHS).  These recommendations are legally binding adding 
significant weight to implementation [36].  The Pharmaceutical Benefit Advisory 
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Committee (PBAC) performs a similar role in Australia for pharmaceuticals, and 
similarly the Medical Services Advisory Committee (MASC) looks at medical 
technologies and procedures.  NICE has the advantage of being able to set its own agenda 
and prioritise evaluation, as well as successfully using a rapid response method, ideal 
when answers are required within short timeframes [37]. 
 
what else influences the decision to accept CAM? 
Rigorous research and economic evaluation of CAM is a necessary step toward 
acceptance and adoption of these medicines and therapies by health care decision makers.  
Other issues, including historical and current public acceptance and demand, practitioner 
acceptance (particularly conventional practitioners), as well as political attitudes, will be 
influential in the decision to incorporate CAM into a comprehensive health care system.  
Conventional practitioners and decision makers have to date tended not to focus on CAM 
[38].  Different practitioner’s beliefs and their exposure to and experience with CAM 
therapies all play a role, and in a sense, despite evidence of efficacy and effectiveness, 
CAM therapies have to repeatedly demonstrate their value [39].  Economic evaluation 
adds weight to the growing evidence base for CAM and will make it harder for CAM and 
its potential benefits to be overlooked in health care provision and practice decision-
making.  
 
 
Conclusions 
Economic evaluation is a decision-making tool for informing clinical practice and health 
policy (aiding informed decision-making regarding CAM and its integration into the 
health care system).  The use of decision analytic modelling as a method of economic 
evaluation is a flexible method well suited to CAM as it does not rely solely on RCTs, 
but combines multiple data sources and can extrapolate beyond the limits of current 
clinical evidence.  Efficacy and cost-effectiveness must be established and the results 
widely distributed in order for CAM to be extensively considered in healthcare decision-
making.  Information about economic evaluation is widely available, however, without 
any formal training CAM practitioners may be challenged in an attempt to utilise these 
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economic evaluation methods.  As with contemporary health research more generally, it 
is certainly important that multidisciplinary teams be deployed in order to share 
disciplinary insights and supplementary research knowledge. One example of how such a 
multidisciplinary approach is being facilitated at a national and international level is 
through initiatives of the Network of Researchers in the Public Health of Complementary 
and Alternative Medicine (NORPHCAM). NORPHCAM has established a health 
economics research stream helping to introduce and facilitate international collaborations 
between health economists, CAM practitioners and a range of other researchers interested 
in developing the economic evaluation of CAM.  Whether examining the use of CAM 
alone or as an integrated component of contemporary health care provision, further 
consideration of economic evaluation as a research tool is required.  This paper provides 
an impetus for those interested to pursue such a worthy goal. 
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Figures 
 
Figure 1 - Example of a decision tree 
Figure 2 - Example of a Markov model 
Figure 3 - Example of a cost effectiveness plane 
 
Tables 
 
Table 1 – Example of an ICER 
 
Intervention Costs QALYs
Current  $ 540 8 
New  $ 550 8.5 
Difference  $  10    0.5 
ICER  $  20 Per QALY 
 
Table 2 – Example of a Transition Matrix (current treatment) 
 
transition matrix Improvement Deterioration Dead 
Improvement 0.70 0.20 0.10 
Deterioration 0.20 0.50 0.30 
Dead 0.00 0.00 1.00 
 
Table 3 – Example of a Transition Matrix (new treatment) 
 
transition matrix Improvement Deterioration Dead 
Improvement 0.80 0.15 0.05 
Deterioration 0.20 0.50 0.30 
Dead 0.00 0.00 1.00 
 
 
 
20 
 
Table 4 – Example of Markov model cycles (current treatment) 
 
Cycle Improvement Deterioration Dead Total 
0 1000 0 0 1000 
1 700 200 100 1000 
2 530 240 230 1000 
3 419 226 355 1000 
 
Table 5 – Example of an ICER for the Markov model 
 
Intervention Costs QALYs 
Current  $496,300  1652.2 
New  $513,550  1782.7 
Difference  $17,250  130.5 
ICER  $132.18  per QALY 
 
 
